Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Rating of “Hold” from Brokerages

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) have been given an average rating of “Hold” by the thirteen ratings firms that are presently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $143.30.

Several equities analysts have recently commented on the stock. SVB Leerink reaffirmed a “market perform” rating on shares of Tandem Diabetes Care in a research report on Monday, April 18th. StockNews.com assumed coverage on shares of Tandem Diabetes Care in a report on Thursday, March 31st. They issued a “hold” rating on the stock. Zacks Investment Research cut shares of Tandem Diabetes Care from a “hold” rating to a “sell” rating and set a $111.00 target price on the stock. in a report on Tuesday, April 26th. Wells Fargo & Company raised their price target on shares of Tandem Diabetes Care from $160.00 to $166.00 and gave the company an “overweight” rating in a research note on Wednesday, February 23rd. Finally, Citigroup dropped their price target on shares of Tandem Diabetes Care from $163.00 to $155.00 and set a “buy” rating on the stock in a research note on Wednesday, February 23rd.

In related news, COO David B. Berger sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 16th. The shares were sold at an average price of $108.37, for a total value of $541,850.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David B. Berger sold 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 1st. The stock was sold at an average price of $117.91, for a total transaction of $117,910.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 8,905 shares of company stock worth $992,325. 4.80% of the stock is currently owned by company insiders.

Large investors have recently modified their holdings of the business. Moors & Cabot Inc. acquired a new stake in shares of Tandem Diabetes Care during the 3rd quarter valued at $25,000. Exane Derivatives acquired a new stake in shares of Tandem Diabetes Care in the 1st quarter valued at $33,000. Byrne Asset Management LLC acquired a new stake in shares of Tandem Diabetes Care in the 4th quarter valued at $34,000. Retirement Planning Co of New England Inc. acquired a new stake in shares of Tandem Diabetes Care in the 4th quarter valued at $48,000. Finally, Altshuler Shaham Ltd acquired a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at $53,000. 97.11% of the stock is owned by institutional investors.

Shares of NASDAQ TNDM opened at $96.48 on Monday. The company has a current ratio of 6.15, a quick ratio of 5.63 and a debt-to-equity ratio of 0.65. The stock has a fifty day moving average price of $111.56 and a 200 day moving average price of $124.03. The company has a market cap of $6.17 billion, a P/E ratio of 419.48 and a beta of 0.52. Tandem Diabetes Care has a 12-month low of $76.19 and a 12-month high of $155.86.

Tandem Diabetes Care (NASDAQ:TNDM – Get Rating) last posted its quarterly earnings data on Tuesday, February 22nd. The medical device company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.04). Tandem Diabetes Care had a net margin of 2.21% and a return on equity of 4.58%. The firm had revenue of $210.00 million during the quarter, compared to analysts’ expectations of $198.83 million. During the same period in the previous year, the company earned $0.24 earnings per share. The business’s quarterly revenue was up 24.9% on a year-over-year basis. On average, sell-side analysts forecast that Tandem Diabetes Care will post 0.56 EPS for the current fiscal year.

About Tandem Diabetes Care (Get Rating)

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Read More